Co-Diagnostics Seeks FDA Clearance for Decentralized Flu/RSV Test
Event summary
- Co-Diagnostics submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx™ PCR Flu A/B & RSV test on August 6, 2026.
- The submission is supported by clinical studies involving over 1,400 patients and analytical programs spanning 27 studies and over 10,000 test runs.
- If approved, the CLIA Waiver would enable use of the test in decentralized point-of-care settings, expanding access to molecular PCR testing outside traditional labs.
The big picture
Co-Diagnostics' submission marks a significant step toward bringing PCR diagnostics closer to patients, aligning with broader industry trends toward decentralized healthcare. The company's focus on accessibility, affordability, and ease of use positions it to capitalize on the growing demand for point-of-care testing solutions. Success hinges on regulatory clearance and subsequent market adoption.
What we're watching
- Regulatory Approval Timing
- The pace at which the FDA reviews and potentially approves Co-Diagnostics' submission will determine the company's ability to commercialize its decentralized testing platform.
- Market Adoption
- Whether healthcare providers and patients will embrace the Co-Dx PCR platform for near-patient testing, given its lower-cost model and cloud-based infrastructure.
- Competitive Positioning
- How Co-Diagnostics' platform differentiates itself from existing decentralized molecular systems in terms of performance, reliability, and market acceptance.